|
|
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
|
|
|
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
|
|
|
T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use
|
|
|
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
|
|
|
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
|
|
|
T2 Biosystems Announces First Quarter 2023 Financial Results
|
|
|
T2 Biosystems Announces Exploration of Strategic Alternatives and the Implementation of a Restructuring Program
|
|
|
T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel
|
|
|
T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023
|
|
|
T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023
|
